HYPOPHOSPHATASIA
Clinical trials for HYPOPHOSPHATASIA explained in plain language.
Never miss a new study
Get alerted when new HYPOPHOSPHATASIA trials appear
Sign up with your email to follow new studies for HYPOPHOSPHATASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Study to see if immune drugs can save fading bone treatment
Disease control TerminatedThis study was designed for people with hypophosphatasia (a rare bone disease) whose treatment with asfotase alfa stopped working because their immune system attacked it. Researchers planned to give immune-suppressing drugs to see if they could restore the treatment's effect. The…
Matched conditions: HYPOPHOSPHATASIA
Phase: PHASE4 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 10:26 UTC
-
New hope for rare bone disease: experimental drug shows promise in Late-Stage trial
Disease control OngoingThis study tests an experimental drug called ALXN1850 in 124 teens and adults with hypophosphatasia (HPP), a rare genetic condition that weakens bones. Participants receive either the drug or a placebo to see if it improves walking distance and daily function over about 6 months.…
Matched conditions: HYPOPHOSPHATASIA
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 10:24 UTC
-
New hope for kids with brittle bones: experimental drug takes on standard therapy
Disease control OngoingThis study tests a new medicine, ALXN1850, against the current standard treatment (asfotase alfa) in 43 children aged 2 to 12 with hypophosphatasia, a rare genetic condition that weakens bones. All children have been on the standard treatment for at least 6 months before joining.…
Matched conditions: HYPOPHOSPHATASIA
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New hope for kids with brittle bones: experimental drug enters final testing
Disease control OngoingThis study tests a new medicine called ALXN1850 in 30 children aged 2 to 12 who have hypophosphatasia, a rare genetic condition that weakens bones. The drug is given as a shot under the skin and compared to a placebo (fake treatment) to see if it helps heal bone problems. All chi…
Matched conditions: HYPOPHOSPHATASIA
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 20, 2026 11:56 UTC